Astrazeneca Plc ADR (AZN)

$193.03 +5.87 (3.14%)
Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modi...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Fax: 44 1223 352 858
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
JuanValdex
JuanValdex Feb. 23 at 1:21 PM
$BFRG About $AZN and the Modella deal, and why it is so important we can pick that up later. its definitely important.
0 · Reply
BreakoutPika
BreakoutPika Feb. 23 at 12:02 PM
$SXTC $EDBL $PBM $AZN "
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 6:29 PM
$AZN vs. $PFE — Growth or value in 2026? 👀 AZN’s stronger growth outlook and ambitious 2030 revenue target could give it the edge, while PFE counters with a higher yield and cheaper valuation. It’s a classic momentum vs. income setup heading into 2026. Which pharma giant fits your strategy better? Full breakdown here 👉 https://www.zacks.com/stock/news/2872955/astrazeneca-vs-pfizer-which-pharma-giant-has-the-edge-in-2026?cid=sm-stocktwits-2-2872955-teaser-34501&ADID=SYND_STOCKTWITS_TWEET_2_2872955_TEASER_34501
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 5:29 PM
$PFE vs. $AZN: Which Pharma Giant Holds More Promise? 🤔 Pfizer's facing a rocky road with declining COVID sales and looming patent cliffs, but its strong pipeline and strategic acquisitions aim to offset these challenges. AstraZeneca's growth targets and robust pipeline shine despite some challenges. AZN’s stock has soared 40.6% over the past year, far outpacing PFE’s 1.8% rise. Full analysis here 👉 https://www.zacks.com/stock/news/2872955/astrazeneca-vs-pfizer-which-pharma-giant-has-the-edge-in-2026?cid=sm-stocktwits-2-2872955-body-34502&ADID=SYND_STOCKTWITS_TWEET_2_2872955_BODY_34502
0 · Reply
Chipwars
Chipwars Feb. 19 at 3:37 PM
$AZN Yep. https://www.fool.co.uk/2026/02/17/below-151-heres-why-astrazenecas-share-price-looks-a-steal-to-me-under-228-62-after-strong-2025-results/
0 · Reply
Chipwars
Chipwars Feb. 19 at 3:33 PM
$AZN If approved, AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting : https://www.stocktitan.net/news/AZN/enhertu-type-ii-variation-application-validated-in-the-eu-as-post-d8lfxfug2zwl.html
0 · Reply
Chipwars
Chipwars Feb. 19 at 3:29 PM
$AZN If approved, AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting : https://www.stocktitan.net/news/AZN/enhertu-type-ii-variation-application-validated-in-the-eu-as-post-d8lfxfug2zwl.html
0 · Reply
BreakoutPika
BreakoutPika Feb. 19 at 3:01 PM
$SXTC $EDBL $PBM $AZN :
0 · Reply
JuanValdex
JuanValdex Feb. 19 at 2:43 PM
$BFRG 3 green days, havent seen that in a while, as a matter of belief , i think we have to go back quite aways to find four in a row.... Could it be possible, to do four ??? green days in a row.... I dont even see bullish post market posts except for my George Bad Boy post. A week ago i was stumbling for something to figure out what would signal a change of trend. Well here we are. Weekly support is 49 and its sort of obvious the 59 is resistance and this is starting to create some volume. Above 59 and it looks like 64 is where a short sale stopper might enter. But there is a old sqaure up at 68. I am going to let this go a day before i write new squares. There still are no known numbers on the $$AZN Modella, deal and we may not find that out for sometime time. In the mean time the stock has seemed to find some legs here even if temporarily and possibly is creating a place where it can change trend.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 2:10 PM
$AZN RSI: 71.20, MACD: 5.4936 Vol: 9.83, MA20: 189.32, MA50: 186.22 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on AZN
AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

Tue, 24 Feb 2026 06:33:39 -0500 - 2 hours ago

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

2026-02-23T13:55:00.000Z - 23 hours ago

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment

2026-02-20T17:29:16.000Z - 3 days ago

AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment

FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer

2026-02-20T13:02:32.000Z - 4 days ago

FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer

AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemia Treatment

2026-02-20T12:28:10.000Z - 4 days ago

AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemia Treatment

CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

2026-02-20T12:00:00.000Z - 4 days ago

CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Treatment

2026-02-20T11:51:09.000Z - 4 days ago

AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Treatment

FDA Approves AstraZeneca's Calquence Plus Venetoclax For Chronic Lymphocytic Leukemia

2026-02-20T08:00:00.000Z - 4 days ago

FDA Approves AstraZeneca's Calquence Plus Venetoclax For Chronic Lymphocytic Leukemia

AstraZeneca (AZN) Strikes Major Licensing Deal in China

2026-02-19T18:59:54.000Z - 4 days ago

AstraZeneca (AZN) Strikes Major Licensing Deal in China

EMA Validates Enhertu Application for AstraZeneca (AZN)

2026-02-19T10:25:39.000Z - 5 days ago

EMA Validates Enhertu Application for AstraZeneca (AZN)

Daiichi Sankyo: ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

2026-02-19T07:36:00.000Z - 5 days ago

Daiichi Sankyo: ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

FDA Implements New Policy for Drug Approval Requirements Impacting AstraZeneca (AZN)

2026-02-18T22:53:04.000Z - 5 days ago

FDA Implements New Policy for Drug Approval Requirements Impacting AstraZeneca (AZN)

FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals

2026-02-18T22:52:10.000Z - 5 days ago

FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals

AstraZeneca (AZN) Partners with Evinova for AI-Driven Drug Development

2026-02-18T15:58:39.000Z - 5 days ago

AstraZeneca (AZN) Partners with Evinova for AI-Driven Drug Development

AstraZeneca, Bristol partner with Evinova to use AI in drug development

2026-02-18T15:30:44.000Z - 5 days ago

AstraZeneca, Bristol partner with Evinova to use AI in drug development

Top 3 Health Care Stocks That May Collapse This Quarter

Wed, 18 Feb 2026 09:04:08 -0500 - 5 days ago

Top 3 Health Care Stocks That May Collapse This Quarter

Apple, Ulta Beauty, AstraZeneca And A Real Estate Stock On CNBC's 'Final Trades'

2026-02-18T13:47:46.000Z - 6 days ago

Apple, Ulta Beauty, AstraZeneca And A Real Estate Stock On CNBC's 'Final Trades'

Impax International Sustainable Economy Fund Q4 2025 Contributors And Detractors

Wed, 18 Feb 2026 08:47:00 -0500 - 6 days ago

Impax International Sustainable Economy Fund Q4 2025 Contributors And Detractors

Final Trades: Apple, AstraZeneca, Vici Properties and Ulta Beauty

2026-02-17T18:17:14.000Z - 6 days ago

Final Trades: Apple, AstraZeneca, Vici Properties and Ulta Beauty

Top global stories this week: AstraZeneca, Unilever, NatWest among major names

2026-02-15T22:00:18.000Z - 8 days ago

Top global stories this week: AstraZeneca, Unilever, NatWest among major names

Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus

2026-02-15T13:05:11.000Z - 9 days ago

Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus

AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results in Asthma Trials

2026-02-13T12:30:19.000Z - 11 days ago

AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results in Asthma Trials

China charges former AstraZeneca executive – what it means for global pharmaceutical firms

2026-02-13T12:00:12.000Z - 11 days ago

China charges former AstraZeneca executive – what it means for global pharmaceutical firms

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

2026-02-12T18:26:00.000Z - 11 days ago

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca

2026-02-12T11:50:42.000Z - 12 days ago

Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca

AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

2026-02-12T01:04:11.000Z - 12 days ago

AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Q4 2025 AstraZeneca PLC Earnings Call Transcript

2026-02-11T23:45:34.000Z - 12 days ago

Q4 2025 AstraZeneca PLC Earnings Call Transcript

Here's How Much $100 Invested In AstraZeneca 5 Years Ago Would Be Worth Today

2026-02-11T20:30:42.000Z - 12 days ago

Here's How Much $100 Invested In AstraZeneca 5 Years Ago Would Be Worth Today

AstraZeneca (AZN) Faces Legal Challenges in China

2026-02-11T19:00:50.000Z - 12 days ago

AstraZeneca (AZN) Faces Legal Challenges in China

Former AstraZeneca regional head officially charged in China

2026-02-11T18:23:57.000Z - 12 days ago

Former AstraZeneca regional head officially charged in China

Notable ETF Inflow Detected - PVAL, AZN, LUV, MCK

2026-02-11T15:53:16.000Z - 12 days ago

Notable ETF Inflow Detected - PVAL, AZN, LUV, MCK

AstraZeneca awards $3.4 million to U.S. nonprofits to expand healthcare access

2026-02-11T14:31:40.000Z - 12 days ago

AstraZeneca awards $3.4 million to U.S. nonprofits to expand healthcare access

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

Wed, 11 Feb 2026 09:00:00 -0500 - 12 days ago

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy

2026-02-10T20:43:09.000Z - 13 days ago

AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy

AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript

2026-02-10T17:44:24.000Z - 13 days ago

AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript

AstraZeneca Cancer Portfolio Dominates Sales With Massive Double Digit Growth

2026-02-10T17:32:49.000Z - 13 days ago

AstraZeneca Cancer Portfolio Dominates Sales With Massive Double Digit Growth

Oakmark International Strategy Updates Portfolio, Adds AstraZeneca (AZN)

2026-02-10T15:00:11.000Z - 13 days ago

Oakmark International Strategy Updates Portfolio, Adds AstraZeneca (AZN)

Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings

2026-02-10T14:30:05.000Z - 13 days ago

Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings

AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat

2026-02-10T14:09:51.000Z - 13 days ago

AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

2026-02-10T13:30:00.000Z - 14 days ago

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

AstraZeneca (AZN) Projects Moderate Revenue Growth by FY26

2026-02-10T13:05:58.000Z - 14 days ago

AstraZeneca (AZN) Projects Moderate Revenue Growth by FY26

AstraZeneca (AZN) Surpasses Q4 Earnings Expectations, Driven by Oncology Growth

2026-02-10T13:00:30.000Z - 14 days ago

AstraZeneca (AZN) Surpasses Q4 Earnings Expectations, Driven by Oncology Growth

AstraZeneca rises as cancer drugs power Q4 beat

2026-02-10T12:39:10.000Z - 14 days ago

AstraZeneca rises as cancer drugs power Q4 beat

AstraZeneca (AZN) Exceeds Revenue Expectations with Strong Growth Outlook

2026-02-10T12:33:36.000Z - 14 days ago

AstraZeneca (AZN) Exceeds Revenue Expectations with Strong Growth Outlook

AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment

2026-02-10T12:26:15.000Z - 14 days ago

AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment

Earnings Snapshot: AstraZeneca beats Q4 revenue estimates; initiates FY outlook

2026-02-10T12:25:32.000Z - 14 days ago

Earnings Snapshot: AstraZeneca beats Q4 revenue estimates; initiates FY outlook

AstraZeneca reports Q4 results

2026-02-10T12:11:30.000Z - 14 days ago

AstraZeneca reports Q4 results

AstraZeneca PLC 2025 Q4 - Results - Earnings Call Presentation

2026-02-10T12:01:07.000Z - 14 days ago

AstraZeneca PLC 2025 Q4 - Results - Earnings Call Presentation

AstraZeneca results: FY and Q4 2025

Tue, 10 Feb 2026 07:00:00 -0500 - 14 days ago

AstraZeneca results: FY and Q4 2025

AstraZeneca CFO: 2025 was an amazing year

2026-02-10T11:51:19.000Z - 14 days ago

AstraZeneca CFO: 2025 was an amazing year

AstraZeneca Forecasts Continued Growth on Pipeline Strength

Feb 10, 2026, 2:34 AM EST - 14 days ago

AstraZeneca Forecasts Continued Growth on Pipeline Strength

AstraZeneca profit climbs on cancer and heart drug demand

Feb 10, 2026, 2:24 AM EST - 14 days ago

AstraZeneca profit climbs on cancer and heart drug demand

Drugmaker AstraZeneca forecasts sales and profit growth in 2026

Feb 10, 2026, 2:06 AM EST - 14 days ago

Drugmaker AstraZeneca forecasts sales and profit growth in 2026

Oakmark International Strategy Q4 2025 New Investments And Divestments

Feb 8, 2026, 12:20 PM EST - 15 days ago

Oakmark International Strategy Q4 2025 New Investments And Divestments

NVS SNY UL

AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

Feb 3, 2026, 2:42 AM EST - 21 days ago

AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

US FDA rejects AstraZeneca's easier-to-use version of lupus therapy

Feb 3, 2026, 2:18 AM EST - 21 days ago

US FDA rejects AstraZeneca's easier-to-use version of lupus therapy

AstraZeneca begins trading on the New York Stock Exchange

Feb 2, 2026, 7:00 AM EST - 22 days ago

AstraZeneca begins trading on the New York Stock Exchange

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

Feb 1, 2026, 2:49 AM EST - 23 days ago

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

Jan 30, 2026, 2:51 AM EST - 25 days ago

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions

Jan 30, 2026, 2:15 AM EST - 25 days ago

World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

Jan 29, 2026, 8:35 PM EST - 25 days ago

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

AstraZeneca sets out $15 billion China investment during Starmer visit

Jan 29, 2026, 5:00 AM EST - 26 days ago

AstraZeneca sets out $15 billion China investment during Starmer visit

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

Jan 28, 2026, 4:01 PM EST - 26 days ago

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

Airbus, AstraZeneca and HSBC executives join UK's Starmer on high-stakes China trip

Jan 27, 2026, 10:59 PM EST - 27 days ago

Airbus, AstraZeneca and HSBC executives join UK's Starmer on high-stakes China trip

HSBC

Astrazeneca CEO Soriot to join Starmer delegation to China, source says

Jan 26, 2026, 7:55 AM EST - 4 weeks ago

Astrazeneca CEO Soriot to join Starmer delegation to China, source says

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

Jan 20, 2026, 11:47 AM EST - 4 weeks ago

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

AstraZeneca to delist from Nasdaq, join NYSE in February

Jan 20, 2026, 2:21 AM EST - 5 weeks ago

AstraZeneca to delist from Nasdaq, join NYSE in February

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Jan 15, 2026, 11:35 AM EST - 5 weeks ago

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

GEHC LLY RNA

AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:15 PM EST - 5 weeks ago

AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AstraZeneca to acquire Modella AI to speed oncology drug research

Jan 13, 2026, 12:10 PM EST - 5 weeks ago

AstraZeneca to acquire Modella AI to speed oncology drug research

Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale

Jan 13, 2026, 12:02 PM EST - 5 weeks ago

Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Jan 10, 2026, 10:00 AM EST - 6 weeks ago

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 6 weeks ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN BMY LLY MRK NVO PFE

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

Jan 8, 2026, 7:12 AM EST - 6 weeks ago

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

Jan 6, 2026, 7:44 AM EST - 7 weeks ago

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.

Jan 2, 2026, 1:55 PM EST - 7 weeks ago

These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.

BK C CAH CVS

AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

Dec 22, 2025, 2:39 AM EST - 2 months ago

AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial

Dec 22, 2025, 2:22 AM EST - 2 months ago

AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 2 months ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN ARGX IBB

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 2 months ago

Trump to announce new drug-pricing deals later today

ABBV AMGN BMY GILD LLY MRK NVO

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

Dec 19, 2025, 2:30 AM EST - 2 months ago

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 2 months ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN BMY LLY NVS PFE

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Dec 15, 2025, 4:29 PM EST - 2 months ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

Dec 10, 2025, 10:26 AM EST - 2 months ago

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Dec 8, 2025, 8:10 AM EST - 2 months ago

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

Dec 4, 2025, 4:00 PM EST - 2 months ago

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

CRM

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Dec 4, 2025, 7:00 AM EST - 2 months ago

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Dec 2, 2025, 9:18 AM EST - 2 months ago

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

BREAKING: Trump strikes major deal with UK on drug pricing

Dec 1, 2025, 10:15 AM EST - 3 months ago

BREAKING: Trump strikes major deal with UK on drug pricing

EWU EWUS FKU FLGB FXB GSK

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

Nov 26, 2025, 12:18 PM EST - 3 months ago

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

NVO

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Nov 24, 2025, 12:58 PM EST - 3 months ago

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

Nov 23, 2025, 7:01 PM EST - 3 months ago

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

JuanValdex
JuanValdex Feb. 23 at 1:21 PM
$BFRG About $AZN and the Modella deal, and why it is so important we can pick that up later. its definitely important.
0 · Reply
BreakoutPika
BreakoutPika Feb. 23 at 12:02 PM
$SXTC $EDBL $PBM $AZN "
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 6:29 PM
$AZN vs. $PFE — Growth or value in 2026? 👀 AZN’s stronger growth outlook and ambitious 2030 revenue target could give it the edge, while PFE counters with a higher yield and cheaper valuation. It’s a classic momentum vs. income setup heading into 2026. Which pharma giant fits your strategy better? Full breakdown here 👉 https://www.zacks.com/stock/news/2872955/astrazeneca-vs-pfizer-which-pharma-giant-has-the-edge-in-2026?cid=sm-stocktwits-2-2872955-teaser-34501&ADID=SYND_STOCKTWITS_TWEET_2_2872955_TEASER_34501
0 · Reply
ZacksResearch
ZacksResearch Feb. 20 at 5:29 PM
$PFE vs. $AZN: Which Pharma Giant Holds More Promise? 🤔 Pfizer's facing a rocky road with declining COVID sales and looming patent cliffs, but its strong pipeline and strategic acquisitions aim to offset these challenges. AstraZeneca's growth targets and robust pipeline shine despite some challenges. AZN’s stock has soared 40.6% over the past year, far outpacing PFE’s 1.8% rise. Full analysis here 👉 https://www.zacks.com/stock/news/2872955/astrazeneca-vs-pfizer-which-pharma-giant-has-the-edge-in-2026?cid=sm-stocktwits-2-2872955-body-34502&ADID=SYND_STOCKTWITS_TWEET_2_2872955_BODY_34502
0 · Reply
Chipwars
Chipwars Feb. 19 at 3:37 PM
$AZN Yep. https://www.fool.co.uk/2026/02/17/below-151-heres-why-astrazenecas-share-price-looks-a-steal-to-me-under-228-62-after-strong-2025-results/
0 · Reply
Chipwars
Chipwars Feb. 19 at 3:33 PM
$AZN If approved, AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting : https://www.stocktitan.net/news/AZN/enhertu-type-ii-variation-application-validated-in-the-eu-as-post-d8lfxfug2zwl.html
0 · Reply
Chipwars
Chipwars Feb. 19 at 3:29 PM
$AZN If approved, AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting : https://www.stocktitan.net/news/AZN/enhertu-type-ii-variation-application-validated-in-the-eu-as-post-d8lfxfug2zwl.html
0 · Reply
BreakoutPika
BreakoutPika Feb. 19 at 3:01 PM
$SXTC $EDBL $PBM $AZN :
0 · Reply
JuanValdex
JuanValdex Feb. 19 at 2:43 PM
$BFRG 3 green days, havent seen that in a while, as a matter of belief , i think we have to go back quite aways to find four in a row.... Could it be possible, to do four ??? green days in a row.... I dont even see bullish post market posts except for my George Bad Boy post. A week ago i was stumbling for something to figure out what would signal a change of trend. Well here we are. Weekly support is 49 and its sort of obvious the 59 is resistance and this is starting to create some volume. Above 59 and it looks like 64 is where a short sale stopper might enter. But there is a old sqaure up at 68. I am going to let this go a day before i write new squares. There still are no known numbers on the $$AZN Modella, deal and we may not find that out for sometime time. In the mean time the stock has seemed to find some legs here even if temporarily and possibly is creating a place where it can change trend.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 2:10 PM
$AZN RSI: 71.20, MACD: 5.4936 Vol: 9.83, MA20: 189.32, MA50: 186.22 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Feb. 18 at 1:41 PM
$AZN Decimal placement is very important!
0 · Reply
BreakoutPika
BreakoutPika Feb. 18 at 12:18 PM
$PBM $AZN $ATOS.X $AREB '
0 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 6:00 PM
$AZN $ATOS.X $AREB $REVB ;;;
0 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 12:05 PM
$PBM $AZN $ATOS.X #
0 · Reply
TaxEagle1040
TaxEagle1040 Feb. 16 at 11:56 PM
$AZN Did more research, AZN changed formulations away from LNP maybe 2 years ago. However, there was a period of time when they infringed by using ABUS' LNP technology.
0 · Reply
maikl_211
maikl_211 Feb. 15 at 9:26 AM
$TM $CSCO $CAT $WFC $AZN
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 13 at 8:43 PM
$AZN Current Stock Price: $204.54 Contracts to trade: $200.0 AZN Feb 20 2026 Call Entry: $5.50 Exit: $7.90 ROI: 44% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Quantumup
Quantumup Feb. 13 at 3:32 PM
Craig-Hallum🏁 $CMPX ~argues Tovecimig already met the ORR 1° of a Ph3 2L BTC study/ PFS/OS data is expected in Mar—expects these data to support a pot '27 comm launch in 2L BTC (models a $1B peak oppy)—+sees sig⬆️pot from early-stage pipeline. $AZN $ BMY $BNTX $DCTH MRK Here's what else Craig-Hallum said in its initiation report: https://x.com/Quantumup1/status/2022332075974488090?s=20
0 · Reply
Jwa68
Jwa68 Feb. 13 at 1:57 PM
$COYA $RDY $AZN $LLY $NVO Great read. Very well composed. Dr Reddy's and David Einhorn both own 9.9% of the company, just under 20% togethor.
0 · Reply
TalkMarkets
TalkMarkets Feb. 13 at 11:47 AM
Coya Therapeutics Stock Poised To Appreciate As Company Advances Superior ALS Therapy $COYA Also $RDY $AZN $LLY $NVO https://talkmarkets.com/content/stocks--equities/coya-therapeutics-stock-poised-to-appreciate-as-company-advances-superior-als-therapy?post=557175&userid=166882
0 · Reply
HydrogenH2
HydrogenH2 Feb. 12 at 5:13 PM
$JNJ $AZN Bozo... it's about scientific stuff !! lol
0 · Reply
Deeznutsswapmeet
Deeznutsswapmeet Feb. 12 at 4:54 PM
$AZN $JNJ This has exactly zero impact on stock prices. Stop posting garbage that has nothing to do with price action today or in the future. If this is your reason for being a bear, your portfolio is dog shiz
0 · Reply